{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:41:24Z","timestamp":1791477684351,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001834","name":"University of Twente","doi-asserted-by":"publisher","award":["Bansal Start-up"],"award-info":[{"award-number":["Bansal Start-up"]}],"id":[{"id":"10.13039\/501100001834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009253","name":"European Association for the Study of the Liver","doi-asserted-by":"publisher","award":["Juan Rodes Ph.D. Student Fellowship"],"award-info":[{"award-number":["Juan Rodes Ph.D. Student Fellowship"]}],"id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-67926-6","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T10:10:03Z","timestamp":1721729403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo"],"prefix":"10.1038","volume":"14","author":[{"given":"Eline","family":"Geervliet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmee","family":"Karkdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"67926_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516\u2013537. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017 (2023).","journal-title":"J. Hepatol."},{"key":"67926_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Investig. 115, 209\u2013218. https:\/\/doi.org\/10.1172\/JCI24282 (2005).","journal-title":"J. Clin. Investig."},{"key":"67926_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea, V. & Friedman, S. L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6, 425\u2013456. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130246 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"67926_CR4","doi-asserted-by":"publisher","first-page":"1083780","DOI":"10.3389\/fimmu.2022.1083780","volume":"13","author":"J Gong","year":"2022","unstructured":"Gong, J., Tu, W., Liu, J. & Tian, D. Hepatocytes: A key role in liver inflammation. Front. Immunol. 13, 1083780. https:\/\/doi.org\/10.3389\/fimmu.2022.1083780 (2022).","journal-title":"Front. Immunol."},{"key":"67926_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","volume":"59","author":"C Brenner","year":"2013","unstructured":"Brenner, C., Galluzzi, L., Kepp, O. & Kroemer, G. Decoding cell death signals in liver inflammation. J. Hepatol. 59, 583\u2013594. https:\/\/doi.org\/10.1016\/j.jhep.2013.03.033 (2013).","journal-title":"J. Hepatol."},{"key":"67926_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fimmu.2019.00893","volume":"10","author":"CJ Weston","year":"2019","unstructured":"Weston, C. J., Zimmermann, H. W. & Adams, D. H. The role of myeloid-derived cells in the progression of liver disease. Front. Immunol. 10, 893. https:\/\/doi.org\/10.3389\/fimmu.2019.00893 (2019).","journal-title":"Front. Immunol."},{"key":"67926_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1152\/physrev.00013.2007","volume":"88","author":"SL Friedman","year":"2008","unstructured":"Friedman, S. L. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125\u2013172. https:\/\/doi.org\/10.1152\/physrev.00013.2007 (2008).","journal-title":"Physiol. Rev."},{"key":"67926_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1046\/j.1440-1746.1999.01928.x","volume":"14","author":"D Li","year":"1999","unstructured":"Li, D. & Friedman, S. L. Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. J. Gastroenterol. Hepatol. 14, 618\u2013633. https:\/\/doi.org\/10.1046\/j.1440-1746.1999.01928.x (1999).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"67926_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1053\/jhep.2002.33162","volume":"35","author":"DM Dambach","year":"2002","unstructured":"Dambach, D. M., Watson, L. M., Gray, K. R., Durham, S. K. & Laskin, D. L. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology 35, 1093\u20131103. https:\/\/doi.org\/10.1053\/jhep.2002.33162 (2002).","journal-title":"Hepatology"},{"key":"67926_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","volume":"61","author":"C Baeck","year":"2012","unstructured":"Baeck, C. et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416\u2013426. https:\/\/doi.org\/10.1136\/gutjnl-2011-300304 (2012).","journal-title":"Gut"},{"key":"67926_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2249.2012.04609.x","volume":"169","author":"D Degre","year":"2012","unstructured":"Degre, D. et al. Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutrophil infiltrates. Clin. Exp. Immunol. 169, 302\u2013310. https:\/\/doi.org\/10.1111\/j.1365-2249.2012.04609.x (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"67926_CR12","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1136\/gutjnl-2013-306294","volume":"63","author":"J Ehling","year":"2014","unstructured":"Ehling, J. et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 63, 1960\u20131971. https:\/\/doi.org\/10.1136\/gutjnl-2013-306294 (2014).","journal-title":"Gut"},{"key":"67926_CR13","doi-asserted-by":"publisher","first-page":"e0169740","DOI":"10.1371\/journal.pone.0169740","volume":"12","author":"P Mulder","year":"2017","unstructured":"Mulder, P., van den Hoek, A. M. & Kleemann, R. The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and non-alcoholic steatohepatitis. PLoS One 12, e0169740. https:\/\/doi.org\/10.1371\/journal.pone.0169740 (2017).","journal-title":"PLoS One"},{"key":"67926_CR14","doi-asserted-by":"publisher","first-page":"e0184694","DOI":"10.1371\/journal.pone.0184694","volume":"12","author":"T Puengel","year":"2017","unstructured":"Puengel, T. et al. Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLoS One 12, e0184694. https:\/\/doi.org\/10.1371\/journal.pone.0184694 (2017).","journal-title":"PLoS One"},{"key":"67926_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/13543784.2018.1442436","volume":"27","author":"F Tacke","year":"2018","unstructured":"Tacke, F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin. Investig. Drugs 27, 301\u2013311. https:\/\/doi.org\/10.1080\/13543784.2018.1442436 (2018).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"67926_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/hep.30249","volume":"69","author":"A Ambade","year":"2019","unstructured":"Ambade, A. et al. Pharmacological inhibition of CCR2\/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology 69, 1105\u20131121. https:\/\/doi.org\/10.1002\/hep.30249 (2019).","journal-title":"Hepatology"},{"key":"67926_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jcmgh.2020.08.012","volume":"11","author":"M Bartneck","year":"2021","unstructured":"Bartneck, M. et al. Roles of CCR2 and CCR5 for hepatic macrophage polarization in mice with liver parenchymal cell-specific NEMO deletion. Cell Mol. Gastroenterol. Hepatol. 11, 327\u2013347. https:\/\/doi.org\/10.1016\/j.jcmgh.2020.08.012 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"67926_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.22952","volume":"50","author":"E Seki","year":"2009","unstructured":"Seki, E. et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 50, 185\u2013197. https:\/\/doi.org\/10.1002\/hep.22952 (2009).","journal-title":"Hepatology"},{"key":"67926_CR19","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/liv.13698","volume":"38","author":"D Yu","year":"2018","unstructured":"Yu, D., Cai, S. Y., Mennone, A., Vig, P. & Boyer, J. L. Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int. 38, 1128\u20131138. https:\/\/doi.org\/10.1111\/liv.13698 (2018).","journal-title":"Liver Int."},{"key":"67926_CR20","doi-asserted-by":"publisher","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","volume":"11","author":"E Lefebvre","year":"2016","unstructured":"Lefebvre, E. et al. Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One 11, e0158156. https:\/\/doi.org\/10.1371\/journal.pone.0158156 (2016).","journal-title":"PLoS One"},{"key":"67926_CR21","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","volume":"67","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L. et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67, 1754\u20131767. https:\/\/doi.org\/10.1002\/hep.29477 (2018).","journal-title":"Hepatology"},{"key":"67926_CR22","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","volume":"72","author":"V Ratziu","year":"2020","unstructured":"Ratziu, V. et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study. Hepatology 72, 892\u2013905. https:\/\/doi.org\/10.1002\/hep.31108 (2020).","journal-title":"Hepatology"},{"key":"67926_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","volume":"22","author":"QM Anstee","year":"2024","unstructured":"Anstee, Q. M. et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study. Clin. Gastroenterol. Hepatol. 22, 124\u2013134. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.003 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"67926_CR24","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.2353\/ajpath.2009.080632","volume":"174","author":"C Mitchell","year":"2009","unstructured":"Mitchell, C. et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am. J. Pathol. 174, 1766\u20131775. https:\/\/doi.org\/10.2353\/ajpath.2009.080632 (2009).","journal-title":"Am. J. Pathol."},{"key":"67926_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","volume":"18","author":"Y Wen","year":"2021","unstructured":"Wen, Y., Lambrecht, J., Ju, C. & Tacke, F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell. Mol. Immunol. 18, 45\u201356. https:\/\/doi.org\/10.1038\/s41423-020-00558-8 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"67926_CR26","doi-asserted-by":"publisher","first-page":"9730","DOI":"10.1038\/s41598-021-88989-9","volume":"11","author":"A Miura","year":"2021","unstructured":"Miura, A., Hosono, T. & Seki, T. Macrophage potentiates the recovery of liver zonation and metabolic function after acute liver injury. Sci. Rep. 11, 9730. https:\/\/doi.org\/10.1038\/s41598-021-88989-9 (2021).","journal-title":"Sci. Rep."},{"key":"67926_CR27","doi-asserted-by":"publisher","first-page":"115740","DOI":"10.1016\/j.bcp.2023.115740","volume":"215","author":"T Luangmonkong","year":"2023","unstructured":"Luangmonkong, T., Parichatikanond, W. & Olinga, P. Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges. Biochem. Pharmacol. 215, 115740. https:\/\/doi.org\/10.1016\/j.bcp.2023.115740 (2023).","journal-title":"Biochem. Pharmacol."},{"key":"67926_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.matbio.2017.12.012","volume":"68\u201369","author":"E Roeb","year":"2018","unstructured":"Roeb, E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 68\u201369, 463\u2013473. https:\/\/doi.org\/10.1016\/j.matbio.2017.12.012 (2018).","journal-title":"Matrix Biol."},{"key":"67926_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051212","author":"E Geervliet","year":"2020","unstructured":"Geervliet, E. & Bansal, R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. https:\/\/doi.org\/10.3390\/cells9051212 (2020).","journal-title":"Cells."},{"key":"67926_CR30","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jconrel.2021.03.016","volume":"332","author":"E Geervliet","year":"2021","unstructured":"Geervliet, E. et al. Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis. J. Control Release 332, 594\u2013607. https:\/\/doi.org\/10.1016\/j.jconrel.2021.03.016 (2021).","journal-title":"J. Control Release"},{"key":"67926_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/17512433.2021.1884068","volume":"14","author":"M Rau","year":"2021","unstructured":"Rau, M. & Geier, A. An update on drug development for the treatment of nonalcoholic fatty liver disease\u2014From ongoing clinical trials to future therapy. Expert Rev. Clin. Pharmacol. 14, 333\u2013340. https:\/\/doi.org\/10.1080\/17512433.2021.1884068 (2021).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"67926_CR32","doi-asserted-by":"publisher","first-page":"7629724","DOI":"10.1155\/2016\/7629724","volume":"2016","author":"R Bansal","year":"2016","unstructured":"Bansal, R., Nagorniewicz, B. & Prakash, J. Clinical advancements in the targeted therapies against liver fibrosis. Mediat. Inflamm. 2016, 7629724. https:\/\/doi.org\/10.1155\/2016\/7629724 (2016).","journal-title":"Mediat. Inflamm."},{"key":"67926_CR33","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","volume":"29","author":"JPH Drenth","year":"2020","unstructured":"Drenth, J. P. H. & Schattenberg, J. M. The nonalcoholic steatohepatitis (NASH) drug development graveyard: Established hurdles and planning for future success. Expert Opin. Investig. Drugs 29, 1365\u20131375. https:\/\/doi.org\/10.1080\/13543784.2020.1839888 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"67926_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cgh.2023.07.013","volume":"22","author":"SM Francque","year":"2024","unstructured":"Francque, S. M., Noureddin, M. & Krag, A. Learnings from the graveyard of phase 2 and 3 nonalcoholic steatohepatitis trials. Clin. Gastroenterol. Hepatol. 22, 16\u201319. https:\/\/doi.org\/10.1016\/j.cgh.2023.07.013 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"67926_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/1871530315666150316120920","volume":"15","author":"T O'Connor","year":"2015","unstructured":"O\u2019Connor, T., Borsig, L. & Heikenwalder, M. CCL2-CCR2 signaling in disease pathogenesis. Endocr. Metab. Immune Disord. Drug Targets 15, 105\u2013118. https:\/\/doi.org\/10.2174\/1871530315666150316120920 (2015).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"67926_CR36","doi-asserted-by":"publisher","first-page":"812431","DOI":"10.3389\/fimmu.2022.812431","volume":"13","author":"S She","year":"2022","unstructured":"She, S. et al. Functional roles of chemokine receptor CCR2 and its ligands in liver disease. Front. Immunol. 13, 812431. https:\/\/doi.org\/10.3389\/fimmu.2022.812431 (2022).","journal-title":"Front. Immunol."},{"key":"67926_CR37","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3389\/fimmu.2019.02852","volume":"10","author":"D van der Heide","year":"2019","unstructured":"van der Heide, D., Weiskirchen, R. & Bansal, R. Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front. Immunol. 10, 2852. https:\/\/doi.org\/10.3389\/fimmu.2019.02852 (2019).","journal-title":"Front. Immunol."},{"key":"67926_CR38","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jhep.2011.10.026","volume":"56","author":"P Ramachandran","year":"2012","unstructured":"Ramachandran, P. & Iredale, J. P. Macrophages: Central regulators of hepatic fibrogenesis and fibrosis resolution. J. Hepatol. 56, 1417\u20131419. https:\/\/doi.org\/10.1016\/j.jhep.2011.10.026 (2012).","journal-title":"J. Hepatol."},{"key":"67926_CR39","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.bbadis.2013.02.007","volume":"884\u2013890","author":"RG Wells","year":"1832","unstructured":"Wells, R. G. Tissue mechanics and fibrosis. Biochim. Biophys. Acta 884\u2013890, 2013. https:\/\/doi.org\/10.1016\/j.bbadis.2013.02.007 (1832).","journal-title":"Biochim. Biophys. Acta"},{"key":"67926_CR40","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.bbadis.2012.11.002","volume":"876\u2013883","author":"JP Iredale","year":"1832","unstructured":"Iredale, J. P., Thompson, A. & Henderson, N. C. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim. Biophys. Acta 876\u2013883, 2013. https:\/\/doi.org\/10.1016\/j.bbadis.2012.11.002 (1832).","journal-title":"Biochim. Biophys. Acta"},{"key":"67926_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810546","author":"HS Lee","year":"2022","unstructured":"Lee, H. S. & Kim, W. J. The role of matrix metalloproteinase in inflammation with a focus on infectious diseases. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms231810546 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"67926_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00424-014-1463-9","volume":"466","author":"Y Ma","year":"2014","unstructured":"Ma, Y. et al. Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch. 466, 1113\u20131127. https:\/\/doi.org\/10.1007\/s00424-014-1463-9 (2014).","journal-title":"Pflugers Arch."},{"key":"67926_CR43","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3892\/ijmm.2018.3516","volume":"41","author":"C Du","year":"2018","unstructured":"Du, C. et al. Transplantation of human matrix metalloproteinase-1 gene-modified bone marrow-derived mesenchymal stem cell attenuates CCL4-induced liver fibrosis in rats. Int. J. Mol. Med. 41, 3175\u20133184. https:\/\/doi.org\/10.3892\/ijmm.2018.3516 (2018).","journal-title":"Int. J. Mol. Med."},{"key":"67926_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11095-007-9311-7","volume":"25","author":"Y Iimuro","year":"2008","unstructured":"Iimuro, Y. & Brenner, D. A. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm. Res. 25, 249\u2013258. https:\/\/doi.org\/10.1007\/s11095-007-9311-7 (2008).","journal-title":"Pharm. Res."},{"key":"67926_CR45","doi-asserted-by":"publisher","first-page":"115612","DOI":"10.1016\/j.biopha.2023.115612","volume":"167","author":"E Geervliet","year":"2023","unstructured":"Geervliet, E., Terstappen, L. & Bansal, R. Hepatocyte survival and proliferation by fibroblast growth factor 7 attenuates liver inflammation, and fibrogenesis during acute liver injury via paracrine mechanisms. Biomed. Pharmacother. 167, 115612. https:\/\/doi.org\/10.1016\/j.biopha.2023.115612 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"67926_CR46","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","volume":"67","author":"O Krenkel","year":"2018","unstructured":"Krenkel, O. et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 67, 1270\u20131283. https:\/\/doi.org\/10.1002\/hep.29544 (2018).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67926-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67926-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T10:24:31Z","timestamp":1721730271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67926-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67926"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67926-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16897"}}